All In Biotech

Drug Trial Radar · NCT07620405

Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease

A Phase III, Multicenter, Open-Label Extension Study to Evaluate the Efficacy and Safety of MHB018A Injection in Subjects With Thyroid Eye Disease

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

219

Planned (sponsor's estimate)

Start

Jul 2027

Primary completion

Jan 2030

Study completion Jan 2031

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Conditions

  • Thyroid Eye Disease (TED)

Interventions

  • MHB018A injectionDrug

    MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proptosis Responder Rate at Week 24Time frame: Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.